Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation

Robert T. Neff, Frank P. Hurst, Edward M. Falta, Erin M. Bohen, Krista L. Lentine, Vikas R. Dharnidharka, Lawrence Y. Agodoa, Rahul M. Jindal, Christina M. Yuan, Kevin C. Abbott

Research output: Contribution to journalArticlepeer-review

125 Scopus citations


Mycophenolate mofetil (MMF) use may be associated with progressive multifocal leukoencephalopathy (PML). We conducted a retrospective cohort study of 32,757 renal transplant recipients using the United States Renal Data System kidney transplant files for the incidence, prognosis, and clinical features associated with PML occurring after kidney transplant. Subjects were transplanted from January 1, 2000 to July 31, 2004 and followed through December 31, 2004. The incidence density of PML in MMF users was 14.4 cases/100,000 person-years at risk versus 0 for non-MMF users (P=0.11) by log rank test. Factors significantly associated with PML were BK virus infection (22.2% vs. 1.1%), pretransplant transfusion (75% vs. 34%), panel reactive antibody more than 20% (56% vs. 14%), and use of antirejection medications in the first year (33% vs. 9.2%), all P less than 0.05. PML is rare in the renal transplant population. There was no significant association between PML and MMF, but MMF use in this cohort is too high to accurately assess an association.

Original languageEnglish
Pages (from-to)1474-1478
Number of pages5
Issue number10
StatePublished - 27 Nov 2008
Externally publishedYes


  • Kidney transplant
  • Mycophenolate mofetil
  • Progressive multifocal leukoencephalopathy


Dive into the research topics of 'Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation'. Together they form a unique fingerprint.

Cite this